GlassScriptPhysician profile
Nicholas A Dutro
NPI 1992024327
$4,245.80
in general payments reported to CMS, 2019-2025
21 companies · $911 in 2025
The $911 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $47.38 · 2022: $63.15 · 2023: $1,834 · 2024: $1,049 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,960 · Food and Beverage: $1,485 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,960.00 |
| Food and Beverage | $1,484.60 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,380.13 | 2019-2025 | |
| Lilly USA, LLC | $415.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $391.31 | 2023-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $230.45 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $151.85 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $109.51 | 2019-2025 | Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.64 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $62.57 | 2019-2025 | Breztri |
| Axsome Therapeutics, INC. | $48.44 | 2024-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $48.06 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.34 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.96 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $45.00 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $38.21 | 2023-2024 | M-M-R II, Gardasil 9, Vaxelis |
| Corcept Therapeutics | $35.03 | 2025 | Korlym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $30.62 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $22.80 | 2019 | |
| Assertio Therapeutics, INC. | $16.77 | 2019 | |
| Corium, LLC | $12.75 | 2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $12.66 | 2019 | |
| Amgen INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Dutro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.